TMCnet

Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today ...
Goldseiten

Noble Plains Uranium Commences Confirmation Drill Program at Shirley Central Project

Noble Plains Uranium Corp. a U.S.-focused uranium exploration and development company, is pleased to announce it has mobilized a drill rig to its Shirley Central Project in Wyoming's prolific Shirley ...
Goldseiten

Americas Uranium Corp. Obtains DTC FAST Eligibility

Americas Uranium Corp. is pleased to announce that its common shares have been confirmed as eligible for the Depository Trust Company's Fast Automated Securities Transfer program. The Company's ...

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease ...